Cancer Society of New Zealand shared on LinkedIn:
“A newly published New Zealand Medical Journal series of articles has found overwhelming support for evidence-based cancer policies among voters across the political spectrum. Whether it is prevention, screening, early detection, treatment or care, New Zealanders back stronger action on cancer regardless of voting intentions. In a policy environment often divided, cancer control is an issue that unites New Zealanders.
The Cancer Society, in partnership with the University of Otago through our research collaboration Te Rōpu Rangahau o te Kāhui Matepukupuku (TRRKM), published the series of peer-reviewed articles in the New Zealand Medical Journal on Friday, 28 August 2026 (Daffodil Day).
The articles are the result of a public opinion survey undertaken last year to inform the development of our election manifesto and election advocacy approach.
The survey of more than 1,600 New Zealanders found:
- High levels of public support for investment in cancer diagnosis, treatment and care
- New Zealanders know prevention is better than cure and strongly support policies such as reinstating the tobacco reforms, introducing measures to create healthier food environments, and stricter alcohol laws to prevent cancer.
- The public wants regulation of commercial industry lobbying in public health policymaking
- Two-thirds of respondents were willing to pay more tax for improved healthcare when funding is dedicated to health.
With an ageing and growing population and persistent inequities in cancer outcomes for Māori, Pacific peoples and those living in areas of greater deprivation, the need for action becomes even more urgent.
This research provides policymakers with clear evidence of broad public support. The question is no longer whether New Zealanders want stronger cancer action. The question is whether decision-makers will act on that mandate.
To find out more about the NZMJ series you can join the free webinar on September 8th by registering here.
The NZMJ papers can be found here.”
This also can be interesting:
FDA Proposes Expedited IND Pilot to Accelerate Early Clinical Development in the United States
